scispace - formally typeset
R

Rosaria Ottanà

Researcher at University of Messina

Publications -  95
Citations -  2935

Rosaria Ottanà is an academic researcher from University of Messina. The author has contributed to research in topics: Aldose reductase & Antimycobacterial. The author has an hindex of 29, co-authored 92 publications receiving 2609 citations.

Papers
More filters
Journal ArticleDOI

5-arylidene-2-imino-4-thiazolidinones : Design and synthesis of novel anti-inflammatory agents

TL;DR: Five derivatives of 5-arylidene-2-imino-4-thiazolidinones exhibited significant activity levels in models of acute inflammation such as carrageenan-induced paw and pleurisy edema in rats, and the ability of such a new class of anti-inflammatory agents to inhibit COX isoforms was assessed in murine monocyte/macrophage J774 cell line assay.
Journal ArticleDOI

Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.

TL;DR: It was found that the substitution pattern on the 5-benzylidene moiety markedly influenced the activity of N-unsubstituted 2,4-thiazolidinediones 2, compounds with substituents at the meta position being generally more effective than the para-subst ituted ones; however, this SAR was not evidenced in acetates 3 and acids 4.
Journal ArticleDOI

In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.

TL;DR: The most interesting result of this research was that some hydrazides and ISNEs proved to be more effective antimycobacterial agents than parental isoniazid in a TB-infected macrophage model.
Journal ArticleDOI

In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I.

TL;DR: The inhibitory effects of some representative 4-thiazolidinones, already widely investigated as potential NSAIDs, on the growth of five human colon carcinoma cell lines with a different COX-2 expression were determined, and it was revealed that 2-phenylimino derivative 3 and 2,4-THiazolidindione 4 were the most active compounds.
Journal ArticleDOI

Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.

TL;DR: In this review, recent advances in the field and promising future directions for developing ARIs are discussed.